Instrument Inactif

Autres langues Nanexa AB (publ) Nasdaq Stockholm

Actions

Bulletin from Nanexa’s Annual General Meeting	15/05
Nanexa receives approval for NEX-22 clinical study	15/05
Nanexa Q1 2024 - Insightful capital markets day	10/05
Equity Research \| NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential	10/05
Nanexa publishes interim report for January-March 2024	03/05
Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05
Invitation to comment on Nanexa's Q1 report 2024	30/04
Nanexa invites to Capital Markets Day on May 7	29/04
Approval of clinical trial application for NEX-22 study delayed	16/04
Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	16/04
Notice of annual general meeting in Nanexa AB (publ)	15/04
Nanexa publishes annual report for 2023	27/03
Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized	22/02
Equity Research \| NANEXA: Focus on dual GLP-1 opportunities and the partner projects	22/02
Nanexa publishes year-end report and Q4 report 2023	21/02
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/02
Invitation to presentation of Nanexa's year-end report and Q4 report 2023	20/02
Equity Research \| NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play	21/12
Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA	20/12
Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA	20/12

Aucun résultat pour cette recherche